

ASX ANNOUNCEMENT

27 OCTOBER 2015



COGSTATE DIRECTOR DR ALAN FINKEL AO NAMED AS CHIEF SCIENTIST OF AUSTRALIA

Cogstate (ASX.CGS) is pleased to congratulate Dr Alan Finkel AO on his appointment to the position of the Chief Scientist of Australia.

Dr Finkel, who recently retired from his role as Chancellor of Monash University, is a respected neuroscientist, electrical engineer entrepreneur and philanthropist. He was named as the Chief Scientist of Australia, in formal announcement issued by the Australian Government <http://science.gov.au/scienceGov/news/Pages/Australia-welcomes-our-next-Chief-Scientist.aspx>.

Given that the role of Chief Scientist is full-time and very demanding, Alan has decided to relinquish all of his Board and management roles, including from the Cogstate Board of Directors, effective 31 December 2015. He intends to retain his significant shareholding in the company.

Dr Finkel joined the Cogstate Board in May 2015 as a non-executive Director and has been an investor in the company since 2009. At the time of joining the Board, he purchased a further 8 million shares via a private placement.

Mr Martyn Myer, Chair of Cogstate said, "On behalf of the Board and Management of Cogstate, I pass on our heartfelt congratulations to Dr Finkel on this important and prestigious appointment. From my long association with Alan I am very confident that he will do an outstanding job in the role.

"Alan has brought a unique blend of skills and experience in technology, business and neuroscience and has made a very meaningful contribution to Cogstate. Alan has been a longstanding and loyal supporter of Cogstate as an investor, and more recently as a non-executive Director. We look forward to continuing our long association with Dr Finkel, and we're very proud of our association with him."

Dr Finkel, has served as the Chancellor of Monash University since January 2008 to October 2015. He has completed doctoral studies in engineering at Monash University, and served as a neuroscience research fellow at the John Curtin School of Medical Research at the Australian National University.

Highlights of Dr Finkel's business career include founding Axon Instruments, a supplier of electronic and robotic instruments for use in neuroscience and drug development. Axon Instruments was acquired by US based Molecular Devices Corporation in for \$140 million in 2003, after which Dr Finkel took on the role of Chief Technology Officer at Molecular Devices.

He has also served as the Chief Technology Officer for Better Place Australia, and is the Executive Chairman of Stile Education, an education technology company based in Melbourne. He is also the co-founder of two science magazines: Cosmos and G:The Green Lifestyle Magazine.

For further information contact:

Brad O'Connor
Cogstate Chief Executive Officer
+613 9664 1300 or 0411 888 347
boconnor@cogstate.com

Kyahn Williamson
Buchan Consulting
0401 018 828
kwilliamson@buchanwe.com.au

ABOUT COGSTATE

Cogstate Ltd (ASX:CGS) is a leading cognitive science company delivering software and services to optimise the measurement of cognition in clinical trials, academic research, healthcare and brain injury. Cogstate is a pioneer in commercialising rapid, reliable and highly sensitive computerised cognitive tests and provides expert support for traditional neurological assessments to drive higher quality outcome measures. Cogstate clients include the world's leading biopharmaceutical companies; military and elite sporting organisations; physicians and patients; renowned academic institutions and public-private partnerships. With more than 90 employees and a global network of expert neurophysiologist consultants across 25 countries, the unique intersection of science, innovation and delivery is at the core of everything we do.

In our clinical trials business, Cogstate provides both software and professional services for clinical research programs seeking to demonstrate a drug's impact on cognition. Cogstate solutions span the clinical trial process from study design to final statistical analysis; and our latest innovation, Precision Recruitment™, is an online pre-screening portal that accelerates the identification of qualified clinical trial participants in high-need indications such as Alzheimer's disease.